Porvair’s membrane filters ensure higher flow rates
Designed to withstand pressure during filtration
The rigorous construction of these pleated membrane cartridges ensures higher flow rates, lower pressure differentials and faster process times, the company says. Independently verified to meet USP Class VI and ISO 10993, each filter is provided with a certificate of quality. Manufacturing takes place in an ISO Class 5 cleanroom in accordance with accredited quality procedures and the membrane is protected from damage during production by the inner and outer drainage layers that maintain the pleat pack structure.
The filter's inner core comprises a thermoplastic material that further supports the pleat pack and draws the filtrate through its perforations to the outlet of the cartridge. Snugly encased in a polymeric outer cage and securely fitted with sanitary design adaptors that provide optimal sealing and safety against bypass, each cartridge is identified by a serial number embossed on the outer sleeve, providing full traceability to all FDA CFR 21 and EC-approved manufacturing components.
The supply chain is closely monitored with in-house production of the filter’s outer cage, core and end cap. Careful attention to package design minimises the chance of damage to the filters during transit and storage, says Porvair.
Assurance of the high quality of Porvair membrane cartridge filters is further demonstrated by post-manufacture integrity testing, which is a non-destructive means of determining oversized pores or defects.
The integrity test parameters employed by Porvair are correlated to the filter's microbial retention capabilities as determined during validation in accordance with ASTM F838-05, HIMA and PDA Technical Reports 26 and 40. Any filter that fails integrity testing is immediately discarded.
Porvair Filtration Group is an international leader in the development and supply of materials and products for applications in filtration and separation. It has offices and manufacturing sites in the UK, Europe and the US and a worldwide network of distributors.
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Read moreHans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Manufacturing
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration
CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
NICE approval is not enough: why the UK’s next medicines challenge is operational delivery
A medicine is not truly accessible until it can be manufactured, procured, stocked, prescribed, dispensed and delivered reliably. That distinction is becoming increasingly important, says Varun Cruz, founder of NEUVIOR